Scientists have confirmed the cannabis ingredient cannabinol (CBN) can increase sleep in rats, highlighting a new path for ...

Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye"), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health ...

This clinical trial is a randomized, double-blind study designed to enroll 120 patients across four treatment groups. The primary endpoint will evaluate the difference in weight loss of nimacimab ...

A member of an Arizona church admitted he molested a boy. The pastor said he knew and never went to the police, flouting ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

ART27.13 is a G-Protein Coupled Receptor (GPCR) agonist, a highly potent, peripherally restricted new chemical entity, ...

It's disappointing." Payton clarified the area that was exploited. "They felt like they had an indication relative to how ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Q3 2024 Earnings Call Transcript November 7, 2024 Skye Bioscience, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.25. Operator: Ladies and gentlemen, thank you for ...

An NC State-led research hub was recently awarded $19 million for continued research on semiconductors for both civilian and military use.

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Placebo-adjusted weight reductions ranged from -8% to -13% at 32 weeks and ... An inverse agonist of the cannabinoid receptor 1 (CB1) receptor; CB1 has been shown to play an important role in ...